Related Experiment Videos
Klatskin tumours: a 20 year experience.
1Department of Surgery, University of Melbourne, Repatriation General Hospital, Heidelberg, Victoria, Australia.
The Australian and New Zealand Journal of Surgery
|January 1, 1989
Summary
This review of 27 cholangiocarcinoma patients shows improved diagnosis and varied treatments over 20 years. Mean survival was 8 months, highlighting the need for better management strategies for this biliary tract cancer.
Area of Science:
- Hepatobiliary Surgery
- Gastroenterology
- Oncology
Background:
- Cholangiocarcinoma of the hepatic confluence presents significant management challenges.
- Jaundice is a common presenting symptom in patients with this condition.
- Treatment strategies have evolved over the past two decades.
Purpose of the Study:
- To review the management of 27 patients with cholangiocarcinoma of the hepatic confluence.
- To document changes in diagnostic accuracy and treatment modalities.
- To analyze survival outcomes associated with different interventions.
Main Methods:
- Retrospective review of 27 patients diagnosed with cholangiocarcinoma of the hepatic confluence.
- Analysis of diagnostic methods and various treatment interventions including T-tube, transhepatic tube, U-tubes, surgical resection, percutaneous drainage, and endoscopic stenting.
- Evaluation of postoperative mortality and patient survival rates.
Main Results:
- All 27 patients presented with jaundice.
- Treatments ranged from palliative procedures (T-tube, transhepatic tube) to surgical resection and more recent minimally invasive techniques (percutaneous drainage, endoscopic stenting).
- Mean survival for 24 actively treated patients was 8 months (range 0-40 months), with six postoperative deaths.
Conclusions:
- Significant advancements in diagnosis and treatment for cholangiocarcinoma of the hepatic confluence have occurred.
- Current treatment modalities offer varied outcomes, with a mean survival of 8 months.
- Further research into optimizing management, potentially including radiotherapy and chemotherapy, is warranted.